X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs TEVA PHARMA (Israel) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   TEVA PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
TEVA PHARMA
Dec-13
PANACEA BIOTECH/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1493,029-   
Low Rs822,631-   
Sales per share (Unadj.) Rs84.11,738.2-  
Earnings per share (Unadj.) Rs-18.3108.6-  
Cash flow per share (Unadj.) Rs-6.7249.1-  
Dividends per share (Unadj.) Rs095.05-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs83.71,930.8-  
Shares outstanding (eoy) m61.25848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.6 84.3%   
Avg P/E ratio x-6.326.1 -24.2%  
P/CF ratio (eoy) x-17.211.4 -151.8%  
Price / Book Value ratio x1.41.5 94.1%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m7,0742,399,704 0.3%   
No. of employees `0002.844.9 6.1%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.132,795.3 5.7%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.72,048.7 -19.9%   
INCOME DATA
Net Sales Rs m5,1541,473,984 0.3%  
Other income Rs m1000-   
Total revenues Rs m5,2541,473,984 0.4%   
Gross profit Rs m-766403,651 -0.2%  
Depreciation Rs m711119,144 0.6%   
Interest Rs m1,50328,951 5.2%   
Profit before tax Rs m-2,881255,556 -1.1%   
Minority Interest Rs m111,161 0.9%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-167,759 -1.1%   
Tax Rs m17-3,120 -0.5%   
Profit after tax Rs m-1,12192,079 -1.2%  
Gross profit margin %-14.927.4 -54.3%  
Effective tax rate %-0.6-1.2 47.8%   
Net profit margin %-21.86.2 -348.3%  
BALANCE SHEET DATA
Current assets Rs m3,810995,523 0.4%   
Current liabilities Rs m8,365868,180 1.0%   
Net working cap to sales %-88.48.6 -1,023.1%  
Current ratio x0.51.1 39.7%  
Inventory Days Days15691 171.5%  
Debtors Days Days6796 70.1%  
Net fixed assets Rs m14,480481,436 3.0%   
Share capital Rs m613,628 1.7%   
"Free" reserves Rs m9030-   
Net worth Rs m5,1271,637,316 0.3%   
Long term debt Rs m5,832753,681 0.8%   
Total assets Rs m19,4333,368,525 0.6%  
Interest coverage x-0.99.8 -9.3%   
Debt to equity ratio x1.10.5 247.1%  
Sales to assets ratio x0.30.4 60.6%   
Return on assets %2.03.6 54.7%  
Return on equity %-21.95.6 -388.9%  
Return on capital %3.64.9 73.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m599234,877 0.3%  
From Investments Rs m-438-83,226 0.5%  
From Financial Activity Rs m-303-281,750 0.1%  
Net Cashflow Rs m-141-130,100 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare PANACEA BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare PANACEA BIOTECH With: ALEMBIC LTD  UNICHEM LAB  STRIDES PHARMA SCIENCE  WYETH LTD  CIPLA  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 13, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS